New Options in Nonhormonal Therapies in Menopause Stephanie Faubion, MD, MBA; Chrisandra L. Shufelt, MD, MS

https://reference.medscape.com/viewarticle/menopause-symptoms-nonhormonal-therapies-recommendations-2026a1000dyx Menopausal vasomotor symptoms (VMS) may significantly impair quality of life, yet many women avoid hormone therapy because of personal preferences or contraindications such as estrogen-sensitive cancers and cardiovascular risk. ReCAP panelists Dr Stephanie Faubion and Dr Chrisandra Shufelt of the Mayo Clinic in Jacksonville, Florida, discuss the evolving landscape of nonhormonal treatment options. They first review the neurokinin receptor antagonists fezolinetant, approved in 2023, and elinzanetant, approved in 2025, which target thermoregulatory pathways in the brain involved in VMS. They emphasize the importance of liver monitoring with these agents.